Getting Into Biotech Investment Banking

Getting Into Biotech Investment Banking

Those interested in a career in Biotech Investment Banking have many options to choose from. There are Equity Research Analysts, Valuation Analysts, Compensation Analysts, and IPO Analysts. Each position requires different skill sets and knowledge. It is important to have a comprehensive understanding of these areas before attempting to enter the field.


IPOs are a milestone in the growth of a healthcare or life science company. The rewards are significant. It is important to have the right bankers on board to help you navigate the process. They can provide you with expert advice on your offering. They can also assist with your accounting and tax planning.

There are several factors to consider when choosing the right bank for your biotech investment banking IPO. You should find a bank that has experience in your industry and that has a good relationship with your management team. Also, make sure that the bank offers specific services that you need.

You should start searching for a bank at least 12-18 months before your IPO timeframe. This way, you can address any questions that your bankers might have about your company. You should also cast your net as wide as possible.


Getting into biotech investment banking can be a fantastic way to change your career. As the biotech industry continues to grow, there are more and more opportunities for candidates with a deep scientific background. You can find positions on job boards, Glassdoor, and LinkedIn, and you can email banks directly to find out if there are any open positions.

A key part of any investment banking program is the internship. As a student, you can tailor your education and internship to fit your specific interests and talents. This can help you stand out in the crowd.

One way to get into biotech investment banking is to enter the industry as an Equity Research Associate. This role is responsible for market research and financial modeling. An Equity Research Associate’s compensation is typically a mid-six figure.

Financial modeling

Investing in biotech firms requires knowledge and skills not taught in traditional finance courses. Financial modeling is the basis of much of this work. This article provides a brief introduction to the topic and serves as a starting point for banking analysts.

Financial modeling is a tool used by corporate finance to estimate the financial performance of a company. It is based on historical data and assumptions. The output of the model can be presented in a variety of ways to give insight into a company’s finances.

Most financial modeling uses spreadsheets. The structure of a model depends on the number of users, the granularity of the data and the required flexibility. Typically, there is a table of contents to help a user navigate a model.

Equity research analyst

Getting an Equity research analyst job in the biotech industry requires a deep understanding of the medical and biotechnology industry. It also requires an in-depth understanding of finance and accounting.

This type of analysis can be a good career choice for those who are interested in a less traditional route to the investment banking industry. With the growth of early-stage biotech companies going public, demand for candidates with a deep scientific background has grown.

The job duties of an Equity research analyst include conducting financial analysis, developing investment models, and writing reports. They may also develop screening tools and trading strategies. A good equity research professional will also have an excellent understanding of how management decisions affect revenue generation. They should be able to present their ideas in a user-friendly manner, so that investors can understand them.


Despite the industry’s relative obscurity, compensation for biotech investment banking is on the rise. In fact, it has been called the pharma industry’s fastest growing sector since the IPOs of 2006. Despite the influx of capital, the biotech industry is also facing a slew of challenges, including shifting ownership and regulatory constraints. For instance, the most recent deal involving AbbVie and Shire was not the biggest flop of the year, but it was a snag that had to be resolved quickly. Luckily, the industry has a large and dedicated pool of talent. As of December, the industry boasted more than 2,000 professionals.

While the big four banks (Goldman Sachs, JPMorgan, Morgan Stanley and Citigroup) are all playing it safe, there are plenty of small boutiques that are taking the high road. For instance, the Options Group is a financial industry recruiting firm that offers the aforementioned woozie.

Jeanette D. Collier